Scarica l'app Stockscreener
13.44
0.22%
-0.03
Dopo l'orario di chiusura:
13.44
Precedente Chiudi:
$13.47
Aprire:
$13.4
Volume 24 ore:
281.30K
Relative Volume:
0.15
Capitalizzazione di mercato:
$208.52M
Reddito:
$10.73M
Utile/perdita netta:
$-455.74M
Rapporto P/E:
-3.7786
EPS:
-3.5569
Flusso di cassa netto:
$-502.70M
1 W Prestazione:
+2.60%
1M Prestazione:
-9.86%
6M Prestazione:
-69.58%
1 anno Prestazione:
-54.85%
Intervallo 1D:
$13.31
$13.71
Intervallo di 1 settimana:
$12.90
$13.90
Portata 52W:
$11.95
$73.06
Atrium Therapeutics Inc Stock (RNA) Company Profile
Nome
Atrium Therapeutics Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare RNA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
13.44 | 208.52M | 10.73M | -455.74M | -502.70M | -3.5569 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | Wells Fargo | Overweight |
| 2025-09-17 | Iniziato | Roth Capital | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Bernstein | Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-06-11 | Iniziato | Raymond James | Strong Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-09-24 | Iniziato | Goldman | Buy |
| 2024-08-28 | Iniziato | Barclays | Overweight |
| 2024-05-03 | Iniziato | BofA Securities | Buy |
| 2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Strong Buy |
| 2021-09-07 | Iniziato | Evercore ISI | Outperform |
| 2021-06-17 | Iniziato | Needham | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | Cowen | Outperform |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | SVB Leerink | Outperform |
| 2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Atrium Therapeutics Inc Borsa (RNA) Ultime notizie
Atrium Therapeutics Inc. (RNA) Stock Price Quote Today & Current Price Chart - Capital.com
Atrium Therapeutics Inc. (RNA) Stock Price Quote Today & Current Price Chart | Capital.com Australia - capital.com
RNA PE Ratio & Valuation, Is RNA Overvalued - Intellectia AI
Fierce Biotech Fundraising Tracker '26: Gilgamesh's $60M series A; Immutrin raises $87M - Fierce Biotech
Mast Multialternative Strategy Fund's Atrium Therapeutics Inc(RNA) Holding History - GuruFocus
Atrium Therapeutics, Inc.(NasdaqGS:RNA) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
RNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Stephanie Kenney Net Worth (2026) - GuruFocus
Novartis acquisition spin-off pioneers RNA therapeutics for the heart - Pharma Voice
Rocio Martin Hoyos Net Worth (2026) - GuruFocus
Brendan R. Winslow Net Worth (2026) - gurufocus.com
Atrium Mortgage Investment (TSE:AI) Given a C$13.12 Price Target at Fundamental Research - Defense World
Stock List: Research Stocks from Around the World - GuruFocus
Atrium Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | RNA | US04965N1046 - marketscreener.com
Finance Watch: Market Struggles On Iran War, Jobs Data, Impacting Biopharma Stocks - Citeline News & Insights
Atrium Therapeutics Inc. (NASDAQ: RNA)Share Price and Research - intelligentinvestor.com.au
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - BioWorld MedTech
Rx Rundown: EveryOne Medicines, Atrium Therapeutics, Moderna and more - Medical Marketing and Media
RNA SEC FilingsAtrium Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Atrium Therapeutics Inc Share Price USD0.001 - Hargreaves Lansdown
Atrium Therapeutics Inc. share price - Capital.com
Atrium Tx launches with Avidity's RNA ticker and cardio assets - bioworld.com
Atrium Therapeutics, Inc. (RNA): An Insightful Analysis of a Biotech Challenger with a $2.28 Billion Market Cap - DirectorsTalk Interviews
Atrium Therapeutics Launches with $270M to Advance RNA Therapies for Rare Genetic Cardiomyopathies - HLTH
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to NASDAQ Composite Index - marketscreener.com
Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions - MedCity News
Novartis completes $12 billion acquisition of Avidity Biosciences - Indian Pharma Post
RNA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off - Trefis
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month LowHere's What Happened - MarketBeat
Q4 Earnings Estimate for CVE:DWS Issued By Atrium Research - Defense World
Novartis completes $12 billion Avidity Biosciences acquisition By Investing.com - Investing.com Canada
Atrium Arises From Novartis’s Avidity Buyout - Citeline News & Insights
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger - Finviz
Merger cashout for Avidity Biosciences (RNA) director Simona Skerjanec - Stock Titan
Avidity Biosciences (RNA) CMO options cashed out in $72 Novartis buyout - Stock Titan
Avidity Biosciences (RNA) CLO disposes stock, options in Novartis merger - Stock Titan
[Form 4] Avidity Biosciences, Inc. Insider Trading Activity - Stock Titan
Merger cash-out: Avidity Biosciences (RNA) officer’s options and shares disposed - Stock Titan
Novartis buyout: Avidity Biosciences (NASDAQ: RNA) director’s equity cashed out - Stock Titan
Avidity Biosciences (RNA) CTO equity disposed in $72 Novartis merger - Stock Titan
Avidity Biosciences shareholders approve merger with Novartis By Investing.com - Investing.com Australia
Novartis (NVS) Backs Atrium Therapeutics' Launch with $270M Funding - GuruFocus
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA - BioPharma Dive
Operating expenses (excl. COGS) of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Avidity-Novartis deal spins out Atrium Therapeutics - The Pharma Letter
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates - Fierce Biotech
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week HighHere's What Happened - MarketBeat
Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates - marketscreener.com
Atrium Therapeutics Launches with $270M - Contract Pharma
Novartis completes acquisition of Avidity Biosciences - TipRanks
Atrium Therapeutics Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):